**Claims**

1. A pharmaceutical formulation comprising an anti-HER2 antibody or a fragment thereof that recognises and binds to human HER2 and which has a heavy chain of SEQ ID NO: 10 and a light chain of SEQ ID NO: 11; an acetate buffer, wherein the acetate buffer is sodium acetate buffer present within the pharmaceutical formulation in an amount of between 1 and 10mM; a surfactant, wherein the surfactant is Polysorbate 80, present within the pharmaceutical formulation in an amount of between 0.001% and 0.1% (w/w); a lyoprotectant, wherein the lyoprotectant is sucrose present within the pharmaceutical formulation in an amount of between 5% and 15% (w/w) or sucrose and mannitol present within the pharmaceutical formulation in an amount of between 5% and 15% (w/w) and 0.5% and 5% (w/w); and a bulking agent, wherein the bulking agent is glycine present within the pharmaceutical formulation in an amount of between 0.5% and 1.5% (w/w) and wherein the pH of the formulation is between 5.0 to 6.0.

2. The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is a liquid formulation, a lyophilized formulation or a reconstituted formulation.

3. The pharmaceutical formulation according to claim 1 or 2, wherein said anti-HER2 antibody or a fragment thereof that recognises and binds to human HER2, is present within said pharmaceutical formulation in an amount of between 10 and 40 mg/ml.

4. The pharmaceutical formulation according to claims 2 or 3, wherein the pharmaceutical formulation is lyophilized and comprises 30mg/ml of an anti-HER2 antibody or a fragment thereof that recognises and binds to human HER2, 12% (w/w) sucrose, 1% (w/w) glycine and 0.014% (w/w) Polysorbate 80 and 5.75mM sodium acetate buffer, wherein the pH of the formulation is 5.7 ± 0.2.

5. The pharmaceutical formulation according to claim 4, wherein the formulation comprises a diluent and is a reconstituted formulation.

6. The pharmaceutical formulation according to claim 5, which comprises 21mg/ml of an anti-HER2 antibody or a fragment thereof that recognises and binds to human HER2, 8.4%

(w/w) sucrose, 0.7% (w/w) glycine, 0.01% (w/w) Polysorbate 80, WFI and 4mM sodium acetate, wherein the pH of the formulation is 5.7 ± 0.2.

7. Use of a pharmaceutical formulation according to anyone of the preceding claims in the manufacture of a medicament for the treatment of a HER2 related disorder selected from a HER2 positive cancer such as metastatic breast cancer, early breast cancer and metastatic gastric cancer.

8. The use according to claim 7, wherein the HER2 related disorder is selected from a HER2 positive cancer such as metastatic breast cancer, early breast cancer and metastatic gastric cancer.

9. The use according to any one of claims 7 to 8, wherein the HER2 related disorder is HER2 positive metastatic breast cancer.

10. An article of manufacture comprising:
(a) a container which holds a lyophilized formulation according to any one of claims 4 to 6; and
(b) instructions for reconstituting the lyophilized formulation with a diluent to an antibody concentration in the reconstituted formulation of about 10 to 40mg/ml.